Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
Marketwatch
-
- tags:
- article_normal
- Biotechnology Services
- Pharmaceuticals
- Insurance
- Non-life Insurance
- Health
- Medical Insurance
- Healthcare
- Life Sciences
- Biopharmaceuticals
- Financial Services
- Government Sponsored Health Insurance
- Corporate Crime
- Legal Action
- Regulation
- Government Policy
- Financial Performance
- Earnings
- Sales Figures
- Corporate
- Industrial News
- Political
- General News
- Crime
- Fraud
- Content Types
- Factiva Filters
- C&E Executive News Filter
- C&E Industry News Filter
- Regeneron Pharmaceuticals Inc.
- REGN
- corporate crime
- legal action
- regulation
- government policy
- financial performance
- earnings
- sales figures
- corporate
- industrial news
- political
- general news
- crime
- fraud
- content types
- factiva filters
- c&e executive news filter
- c&e industry news filter
- biotechnology services
- pharmaceuticals
- insurance
- non-life insurance
- health
- medical insurance
- healthcare
- life sciences
- biopharmaceuticals
- financial services
- government sponsored health insurance